Dr. Steven G. Deeks, MD
Medical Oncology (Medical Oncology Physician)
At a glance
- In the NPI registry since
- 2006
Licensed in California since 1992, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CA license G73895 (first issued 1992; current) -
Internal Medicine Physician
CA license G73895 (first issued 1992; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in San Francisco, CA | 124 |
| Tivicay (dolutegravir sodium) | 120 |
| Descovy (emtricitabine/tenofov alafenam) | 111 |
| Biktarvy (bictegrav/emtricit/tenofov ala) | 85 |
| Odefsey (emtricitab/rilpiviri/tenof ala) | 48 |
| Gabapentin Other prescribers in San Francisco, CA | 43 |
| Ritonavir | 40 |
| Finasteride Other prescribers in San Francisco, CA | 39 |
| Acyclovir Other prescribers in San Francisco, CA | 35 |
| Benazepril-Hydrochlorothiazide (benazepril/hydrochlorothiazide) Other prescribers in San Francisco, CA | 35 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 9 payments worth $5,115 in total to this clinician.
| Viiv Healthcare Company | $5,115 |
|---|
| Consulting Fee | $3,900 |
|---|---|
| Travel and Lodging | $1,013 |
| Food and Beverage | $203 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Viiv Healthcare Company Jul 23, 2025 | Consulting Fee | $3,900 |
| Viiv Healthcare Company Nov 16, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $753 |
| Viiv Healthcare Company Nov 16, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $228 |
| Viiv Healthcare Company Nov 16, 2025 | Travel and Lodging travel to Chicago, IL · in-kind | $31.41 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $37,724 in research payments for these studies, mostly to the institutions running them.
- Pharmacokinetics Distribution of Raltegravir using Radiolabeling in HIV-infected Patients by PET/MR: a Pilot Study.
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.